DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Bristol Myers - 2 Roche - 2 Johnson - 2 Helen Torley - 2 Dado Ruvic - 1 Opdivo - 1 Gina Fusaro - 1 Leroy Leo - 1
Top related locs:
Bengaluru Ljubljana Darzalex Diego
Top related orgs:
Bristol - 2 Bristol Myers Squibb - 2 REUTERS - 2 U.S - 2 Thomson - 2 Therapeutics - 1 Wall Street - 1 Merck & Co - 1

Search resuls for: "Helen Torley"


2 mentions found


☆ Bristol Myers' injectable form of Opdivo meets main goal in kidney cancer trial
  + stars: | 2023-10-19 | by ( ) www.reuters.com   time to read: +2 min
Test tubes are seen in front of a displayed Bristol Myers Squibb logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo Acquire Licensing RightsOct 19 (Reuters) - Bristol Myers Squibb (BMY.N) said on Thursday the injectable form of its blockbuster cancer drug Opdivo met the main goal in trial that had patients with a type of kidney cancer. "We believe this new option, given as a single injection administered in less than five minutes, could transform the treatment experience for both patients and physicians," Gina Fusaro, an executive at Bristol Myers Squibb, said. The trial also showed a non-inferior response rate to the subcutaneous drug, compared to its intravenous form. Bristol Myers now plans to discuss with regulators the next steps for submission and approval of subcutaneous injections for multiple types of cancers.
Persons: Bristol Myers, Dado Ruvic, Opdivo, Gina Fusaro, Roche, Johnson, Helen Torley, Leroy Leo, Anil D'Silva, Shinjini, Shounak Organizations: Bristol, Bristol Myers Squibb, REUTERS, Therapeutics, U.S, Thomson Locations: Bengaluru
☆ Focus: Drugmakers go under the skin, skirting early US Medicare price negotiations
  + stars: | 2023-07-28 | by ( Michael Erman | ) www.reuters.com   time to read: +5 min
Each year, Medicare will add more drugs to the list, the names of which have not yet been disclosed. Faspro, launched in 2020, already accounts for more than 80% of Darzalex revenue, which is due to rise to $9.5 billion this year. Merck previously told Reuters it expects this version of Keytruda could replace the more time consuming infusion for most patients. Keytruda revenue is expected to top $24 billion this year and could exceed $30 billion as soon as 2026, according to analyst estimates. The company has said its expects revenue from subcutaneous drugs containing hyaluronidase to drive its growth going forward.
Persons: Srdjan, Johnson, drugmakers, Bristol Myers, Roche, Biden’s, Michael DiFiore, DiFiore, Joseph Wolk, Faspro, Halozyme, Helen Torley, hyaluronidase, Michael Erman, Patrick Wingrove, Caroline Humer, Bill Berkrot Organizations: U.S, REUTERS, Wall Street, Merck & Co, Halozyme Therapeutics, Reuters, Bristol, Bristol Myers Squibb, Medicare, U.S . Centers, Medicaid Services, J, Reuters Graphics Merck, Merck, Thomson Locations: Ljubljana, Darzalex, Diego
0 next >>
Total: 2